上海丹羿投资管理合伙企业是国内私募投资管理机构，成立于2015年4月，实缴资本金1000万。公司于 2015年在中国证券投资基金业协会管理备案编号：P1015236公司核心高管均从事投研工作十年以上， 在华宝兴业基金、国投瑞银基金、国金证券等机构担任过投资经理或首席研究员，期间管理基金规模数 十亿，名列前茅 2）三诺生物 （上海丹羿投资参与公司特定对象调研） 个股亮点：公司二代测序工程样机已完成，实现核心试剂、辅助试剂及辅助酶试剂全方位自产自研，芯 片加工修饰、文库制备完成，生物性满足基本测试需求，拥有单光道、片上汇流、无疤痕测序等相关专 利技术；公司正全面推进产品矩阵、技术研发、客户服务、办公数据等与DeepSeek等人工智能平台的 深度融合,在实验室自动化领域，亚辉龙iTLA Max全场景智慧生态解决方案系统与DeepSeek等AI技术平 台的融合不断深化 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。 根据市场公开信息及8月28日披露的机构调研信息，知名私募丹羿投资近期对2家上市公司进行了调研， 相关名单如下： 个股亮点：三诺生 ...

Core Viewpoint - Sanofi Biotech has established itself as a leader in the diabetes management sector, focusing on innovative solutions and expanding its product offerings to enhance patient care and health outcomes [1][2]. Group 1: Company Overview - Sanofi Biotech is recognized as the "first stock" in China's blood glucose industry and ranks as the fourth largest blood glucose meter company globally [1]. - The company serves over 25 million users worldwide, with products and services available in 187 countries and regions [1]. - In China, more than 50% of individuals who self-monitor their blood glucose levels use Sanofi's products [1]. Group 2: Strategic Direction - The company is extending its focus into diabetes medical services, emphasizing a digital management model that integrates biosensing, IoT, smart healthcare, and lifestyle guidance [2]. - Sanofi aims to shift diabetes management from a disease-centered approach to a health-centered approach, as outlined in the National Health Commission's plan for diabetes prevention and treatment from 2024 to 2030 [2]. Group 3: Product Development - Continuous Glucose Monitoring (CGM) systems are identified as a critical area for strategic development, providing comprehensive and reliable blood glucose information [2]. - Sanofi has completed the development of its second-generation CGM product, which has been launched domestically and received EU CE-MDR certification for sales in EU-recognized countries [3]. - The company is integrating artificial intelligence into chronic disease management, with its SinoGPT technology already operational [3]. Group 4: Future Investments - A global R&D center is set to be established, with an anticipated investment of 500 million yuan, focusing on the biosensing industry chain [3]. - Future R&D efforts will include artificial pancreas and insulin pump technologies to provide comprehensive solutions for chronic disease management [3].

近日，三诺生物（300298）副董事长李心一在2025西普会上接受记者采访时表示，创业初期让糖尿病患 者用上血糖仪只是第一步，随着不断发展，公司一直积极向糖尿病医疗服务领域延伸。位于湖南长沙的 三诺全球研发中心即将落成，接下来会持续推动可穿戴、高端植入医疗设备的研究开发。 作为中国血糖行业"第一股"，三诺生物已成为全球第四大血糖仪企业。目前公司全球用户超过2500万， 产品和服务覆盖187个国家和地区。根据中康资讯的最新数据，在中国有超过50%的糖尿病自我监测人 群使用着三诺的产品。 "对三诺来说，让糖尿病患者用上血糖仪只是第一步。"李心一表示，"三诺一直积极向糖尿病医疗服务 领域延伸，打造'生物传感+物联网+智慧医疗+健康生活方式引导'的糖尿病及相关慢病数字管理模式， 聚焦动态血糖仪的创新研发。" 糖尿病全病程管理对糖尿病患者而言至关重要，国家卫生健康委印发的《健康中国行动—糖尿病防治行 动实施方案（2024—2030年）》明确提出推进糖尿病防治从"以治病为中心"向"以健康为中心"转变的思 路，要及早干预治疗糖尿病肾病、糖尿病视网膜病变、糖尿病足等并发症，延缓并发症进展，降低致残 率和致死率。 在海外已成主 ...